Peter Wehrwein

A joint statement from the two Democrats senators says prescription drug reform would save the federal government $288 billion over the next 10 years.

Researchers calculated that buying 77 generic drugs at prices being charged by Mark Cuban’s online pharmacy prices would have significantly lowered Medicare spending on those drugs.

Epic research suggests that like COVID-19, flu and other viral pneumonias can result in long-term symptoms like fatigue and brain fog. Why that might be is open question.

The American College of Cardiology and patient groups pushed the PBM to reverse its decision to take Eliquis off its formularies. CVS Caremark says it changed course after negotiating a lower net price.

Recent research has shown less than 1% of patients at high risk for experiencing severe COVID-19 who were treated with Paxlovid (nirmatrelvir and ritonavir) experienced a second bout of COVID-19.

The Federal Trade Commission says its inquiry “will shed light on” clawbacks, potentially unfair audits, rebates and other business practices of the pharmacy benefits management (PBM) industry. Today’s announcement says the commission will be requiring information from the six largest PBMs.

Findings in show that new formulations were more likely for blockbuster drugs and drugs that received accelerated approval. Proxy measures of clinical usefulness and other elements of therapeutic value were not associated with new formulations.

Recent treatment may affect the antibody response, particularly among those with hematologic cancers.

Some evidence suggests that people with HIV may be more likely to develop a severe case of COVID-19 and antiretroviral therapy may provide some protection against infection.

Administered as an injection every other month, Apretude gives people at risk of contracting HIV a PrEP alternative to taking daily pills.

The FDA approved efgartigimod, which is being sold under the brand name Vyvgart and could foment price competition with Soliris (eculizumab) and other treatments usually reserved for severe or refractory cases.

Two key health provisions in the House “BBB “ would empower CMS to negotiate the prices of 10 drugs starting in 2023 and put a limit of $2,000 on Medicare Part D annual out-of-pocket costs.

In an opinion piece published in the Annals of Internal Medicine, community pharmacists were credited with helping to mitigate the spread of coronavirus throughout Taiwan.